A neuromuscular drug candidate acquired by Novartis (NVS) through its $12 billion Avidity Biosciences deal missed its primary endpoint in a late-stage trial, raising fresh questions about the durability of the Swiss drugmaker’s pipeline investments. The failure compounds investor concern about...